Shares of Zimmer Biomet Holdings Inc. tumbled 11.62% to $90.48 Monday, on what proved to be an all-around dismal trading ...

Johnson & Johnson (NYSE:JNJ) engages in the research and development, manufacture, and sale of various products in the ...

Alright, look, lately, we can’t go a day without hearing some widespread misperceptions about stock ownership. I gotta tell ...

We recently compiled a list of the 10 Most Profitable Cheap Stocks to Buy Now. In this article, we are going to take a look ...

Dividend stock investing has long been a cornerstone for building wealth, offering investors a steady stream of passive ...

When investors think about how they want to structure their portfolios in this current environment, a few things may come to ...

UnitedHealth has shed almost $200 billion in market value over the last five months. More customers and more business lines ...

The Financial Times reports today that histotripsy tech developer HistoSonics is considering a potential sale after receiving ...

Read here for Yacktman's Q1 2025 portfolio trends, top holdings, stake changes, and strategies with highlights on Canadian ...

强生 (JNJ.US)宣布，美国FDA已批准其抗体疗法Imaavy (nipocalimab)上市，用于治疗抗AChR、抗MuSK抗体阳性的全身性重症肌无力 (gMG)成人与12岁以上儿童患者。根据新闻稿，该疗法是获批用于治疗该类患者群体的首款新生儿Fc受体 (FcRn)阻断剂。

We recently published a list of The Best and Worst Dow Stocks for the Next 12 Months. In this article, we are going to take a ...

Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior ...